Home Diagnostics appoints Joseph Capper president, CEO and director
FORT LAUDERDALE, Fla. Home Diagnostics, Inc. on Monday appointed Joseph Capper as lead executive of the diabetes diagnostics companies. Capper was named president, CEO and director.
Capper succeeds J. Richard Damron, Jr., who served in the same capacity since 2001 and will be departing the company.
“On behalf of the board, I would like to thank [Damron] for his commitment and assistance during this transition period,” stated George Holley, HDI chairman. “We extend our best wishes to him and appreciate the leadership he provided to Home Diagnostics during the last eight years, which includes the company’s successful public offering.”
“I am pleased to appoint Joe Capper to the positions of CEO and president of Home Diagnostics and welcome him to the board,” Holley added. “[Capper] garnered extensive experience in the diabetes industry during his tenure at Bayer and CCS Medical, and has an understanding of our distribution channels as well as operations and supply chain management. [Capper] is the ideal leader to join our existing strong management team in order to move Home Diagnostics to the next stage of growth by maximizing our current product expansion and capitalizing on the strength of our distribution network.”
“I have been familiar with Home Diagnostics as a business partner for many years and look forward to leveraging my experience in the field to help accelerate the growth and expansion of our business,” Capper said. “I have great respect for the company’s ability to innovate, the product portfolio and the market position they have achieved in the industry. I am extremely excited about the opportunity to join the Home Diagnostics team and look forward to capitalizing on our strong product line and market position.”
Capper most recently was president and CEO of CCS Medical, a medical supply management company, from 2003 to 2008. Under his leadership, CCS Medical’s annual sales grew from approximately $60 million to over $500 million. Additionally, he was responsible for acquiring and integrating Becton Dickenson’s blood glucose monitoring division into the CCS product line and commercializing it under the Nova Max brand.
Prior to joining CCS, Capper worked with Bayer Healthcare’s diabetes care division, where he served as the division’s national sales director. He holds a Bachelor of Science in Accounting from West Chester University and an MBA in International Finance from George Washington University.
Baby Vibe unveils gum massaging product for teething children
THOUSAND OAKS, Calif. Baby Vibe on Monday announced its new option for parents seeking teething relief for their children, the JeJe Teether, a product that creates a vibrating sensation that massages aching gums and eases the process of cutting teeth. The vibrations last seven minutes before JeJe Teether switches off automatically.
“The vibration produced by the JeJe Teether actually stimulates gum tissue and facilitates the tooth breakthrough process quite naturally,” stated Mario Gonzalez, co-founder of Baby Vibe. “So the function of the JeJe Teether is twofold: It relieves the pain and shortens the window in which the baby can experience pain.”
Study shows fish oils improve cholesterol levels in athletes
BIRMINGHAM, Ala. According to a clinical study published in January in the inaugural issue of Sports Health: A Multi-Disciplinary Approach, fish oils dramatically improved cholesterol levels in professional football players.
The two-year study titled Evaluation of Lipid Profiles and the Use of Omega-3 Essential Fatty Acid in Professional Football Players evaluated 36 professional NFL football players, ages 23 to 41, from the Pittsburgh Steelers. Researchers assessed emerging cardiovascular risk factors, as found in the specialized VAP Cholesterol Test, to determine whether omega-3 essential fatty acids found in fish oil can reduce these factors.
During a two month period of the regular 2006-2007 football season, each participant in the treatment group was given 2,560 mg/day of mixed EPA/DHA omega-3 fatty acid supplements in the form of fish oil soft gels.
Results showed that the omega-3 oil raised the athletes’ high-density lipoproteins and lowered triglycerides and other atherogenic subfractions. Elevated levels of triglycerides are associated with diabetes and cardiovascular disease. These results suggest a strong benefit for lessening heart disease risk factors in football players and possibly other athletes throughout their active years, study authors said.